Chargeurs

Support Services / France

Q3 performance confirms our FY view

Earnings/sales releases - 11/11/2021


Chargeurs released a solid set of results in Q3, with Protective Films continuing to perform strongly and Fashion Technologies showing signs that the recovery is picking up pace. The Museum activity will see a new addition to bolster its offer following the acquisition of Event Communications and Luxury Materials marks its return to pre-pandemic levels. All these elements support our upbeat FY21 view, although cost and raw material pressures loom over next year's outlook.

Fact

Chargeurs reported group revenues of €173m in Q3 21, up +0.7% Ifl versus CHSdriven 2020, but +14.2% Ifl versus the more normalised 2019 level. Protective Films saw top-line growth of 27.6% Ifl to €86.2m, slightly above our current expectations. Fashion Technologies continued in its recovery, with revenues standing only 15.7% below the pre-pandemic result and +19.5% Ifl above Q3 20. Luxury Materials saw revenues more than double yoy to return back to the 2019 level (+2.8%). Museum Solutions was nearly flat yoy (-0.8%). Lastly, Healthcare Solutions posted sales of €11.3m, in line with a normalisation in the demand for PPE.

Revenue break-down by division

	Q3			chg. 2021 vs. 2020		chg. 2021 vs. 2019	
€m	2021	2020	2019	reported	like-for-like	reported	like-for-like
Protective Films	86.2	67.1	69.8	+28.5%	+27.6%	+23.5%	+24.9%
PCC Fashion Technologies	39.1	32.9	48.5	+18.8%	+19.5%	19,4%	-15.7%
Luxury Materials	22.1	9.8	21.5	+125.5%	+120.4%	+2.8%	+2.8%
Museum Solutions	14.2	13.2	6.6	+7.6%	-0.8%	+115.2%	(14.0%
Chargeurs excl. Healthcare Solutions	161.6	123.0	146.4	+31.4%	+29.8%	+10.4%	+6.5%
Healthcare Solutions	11.3	46.7	-	-75.8%	-75.8%		
Chargeurs	172.9	169.7	146,4	+1.9%	+0.7%	+18.1%	+14.2%



Analysis

Protective Films on its way to a record year

CPF continued to show strong momentum, with volume growth led by the construction sector in Europe and Asia, and pricing increases across the board to account for the surge in the price of polyethylene. We currently forecast a record top-line of €331m for the division in FY21, which we see as easily attainable judging by the solid Q3 execution. However, high PE prices will continue to exert pressure on margins, as not all sales are covered by pass-through clauses, which is reflected in our estimates as we expect the division's recurring operating margin to remain below the 10% target level until 2023.

Encouraging signs of recovery for Fashion Technologies

The division saw a strong rebound in activity yoy, driven by a strong performance in the US, where sales are now above the pre-pandemic level. The group notes that the commercial success of a recently launched line of interlinings was also a leading factor to the quarterly improvement. Revenues of \in 39.1m came in above our estimates which may warrant an adjustment to our FY forecasts, as the return of the order book to the 2019 level shows that the recovery is picking up pace and provides confidence on a stronger Q4 showing.



Jorge VELANDIA supportservices@alphavalue.eu

+33 (0) 1 70 61 10 50 cs.alphavalue.com

Company Page

This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Buy	Upside: 23.1%
Target Price (6 months)	€ 35.6
Share Price	€ 28.9
Market Cap. €M	705
Price Momentum	STRONG
Extremes 12Months	15.4 🕨 28.9
Sustainability score	3.2 /10
Credit Risk	BB 🛪
Bloomberg	CRI FP Equity
Reuters	CRIP.PA



Download Full Analysis

PERF	1 w	1	m	3m	12m
Chargeurs	11.9%	10	.5%	33.0%	80.1%
Support Services	0.87%	4.4	19%	0.92%	21.8%
STOXX 600	0.53%	5.7	73%	2.42%	25.8%
Last updated: 23/09/2021	12/20	A	12/21E	12/22E	12/23E
Adjusted P/F (x)	9 (00	26.3	20.4	18.1

23/09/2021		/	/	/_0_
Adjusted P/E (x)	9.00	26.3	20.4	18.1
Dividend yield (%)	8.34	2.07	2.25	2.49
EV/EBITDA(R) (x)	5.48	11.9	10.4	8.71
Adjusted EPS (€)	1.76	1.10	1.42	1.60
Growth in EPS (%)	167	-37.6	29.3	12.6
Dividend (€)	1.32	0.60	0.65	0.72
Sales (€M)	822	705	769	839
Underlying operat. profit ma	9.65	6.78	7.70	8.27
Attributable net profit (€M)	41.0	25.5	33.2	37.6
ROE (after tax) (%)	17.5	11.1	13.8	13.5
Gearing (%)	75.7	93.4	77.3	59.6
Company Valuation - Company Financials				



External growth strategy continues at Museum Solutions

CMS announced a new bolt-on acquisition to enforce its museum services activity, UK-based Event Communications Ltd. This new addition brings expertise in museum design and project planning, bolstering CMS's position as a clear leader in this high-value added niche market. The division's Q3 revenues (€14.2m) showed a progressive recovery of the legacy non-museum activities thanks to the reopening of retail spaces and the return of trade shows and events.

Healthcare Solutions subject to the vagaries of COVID-19

As expected, the advancement in the vaccination campaign and improvements in the health situation have resulted in a cool-down in the demand for personal protective equipment (PPE). Naturally, revenues from this activity have declined substantially compared to the COVID-19-driven 2020 levels, although CHS's current framework agreements for the supply of PPE have generated €11.3m in turnover in Q3. While we could expect a similar performance in Q4, supporting our FY21 forecast of €92.0m, the FY22 outlook may warrant a reality check, as the group's diversification efforts into other health and wellness businesses could take some time to pick up pace.

Impact

Our FY21 group revenue estimate of €705m is fully aligned with management's guidance for revenues "to exceed €700m" this year, hence we will not be making significant changes to our current forecasts. Nonetheless, we will readjust the breakdown among the different divisions based on the trend shown in Q3 and expectations for the remainder of the year. This should not have a significant effect in our target price and recommendation.

Sales by Geography



Europe (62.2%)
Americas (19.1%)
Asia (18,7%)

Valuation Summary

Benchmarks	Value	Weight
DCF	€ 38.7	35%
NAV/SOTP per share	€ 38.9	20%
EV/Ebitda	€ 30.8	20%
P/E	€ 26.5	10%
Dividend Yield	€ 36.9	10%
P/Book	€ 36.0	5%
TARGET PRICE	€ 35.6	100%

Largest comparables

- AkzoNobel
- Rentokil Initial
- Quadient
- Teleperformance
- Bureau Veritas

NAV/SOTP Calculation

Balance Sheet		12/20A	12/21E	12/22E
		12/20/1		
Goodwill	€M	191	197	204
Total intangible	€M	229	235	242
Tangible fixed assets	€M	83.1	90.1	97.1
Financial fixed assets	€M	7.00	7.00	7.00
WCR	€M	19.6	18.2	18.3
Other assets	€M	71.4	35.0	37.0
Total assets (net of short term liab.)	€M	456	433	449
Ordinary shareholders' equity	€M	237	224	257
Quasi Equity & Preferred	€M			
Minority interests	€M	-0.80	0.00	0.00
Deside in a ferrar state	CM	40.0	40.0	40.4

	CIVI	400	400	
Ordinary shareholders' equity	€M	237	224	257
Quasi Equity & Preferred	€M			
Minority interests	€M	-0.80	0.00	0.00
Provisions for pensions	€M	16.8	18.2	18.4
Other provisions for risks and liabilities	€M	0.40	0.40	0.40
Total provisions for risks and liabilities	€M	17.2	18.6	18.8
Tax liabilities	€M	-30.5	-30.0	-30.0
Other liabilities	€M	22.2	13.4	13.4
Net debt (cash)	€M	211	207	190
Total liab. and shareholders' equity	€M	456	433	449
Capital Employed				
Capital employed after depreciation	€M	377	389	404
Profits & Risks Ratios				
ROE (after tax)	%	17.5	11.1	13.
ROCE	%	14.3	8.76	10.4
Gearing (at book value)	%	75.7	93.4	77.
Adj. Net debt/EBITDA(R)	х	2.43	3.37	2.7
Interest cover (x)	х	8.62	4.64	5.5
Valuation Ratios				
Reference P/E (benchmark)	x	9.00	26.3	20.
Free cash flow yield	%	16.3	5.21	5.7
P/Book	х	1.54	3.02	2.6
Dividend yield	%	8.34	2.07	2.2
EV Calculation				
Market cap	€M	366	675	67
+ Provisions	€M	17.2	18.6	18.
+ Unrecognised acturial losses/(gains)	€M	0.00	0.00	0.0
+ Net debt at year end	€M	173	168	15
+ Leases debt equivalent	€M	38.1	38.9	39.
- Financial fixed assets (fair value)	€M	32.3	32.3	32.
+ Minority interests (fair value)	€M	0.00	0.00	0.0
= EV	€M	562	868	85
EV/EBITDA(R)	x	5.48	11.9	10.
EV/Sales	х	0.68	1.23	1.1

Analyst : Jorge Velandia, Changes to Forecasts : 23/09/2021.

Consolidated P&L Accounts		12/20A	12/21E	12/22E
Sales	€M	822	705	769
Change in sales	%	31.3	-14.3	9.06
Change in staff costs	%	5.36	9.75	7.31
EBITDA	€M	102	73.1	82.5
EBITDA(R) margin	%	12.5	10.4	10.7
Depreciation	€M	-20.6	-20.8	-19.9
Underlying operating profit	€M	79.3	47.8	59.2
Operating profit (EBIT)	€M	55.8	39.8	51.2
Net financial expense	€M	-9.50	-10.5	-11.0
of which related to pensions	€M	-0.30	-0.20	-0.28
Exceptional items & other	€M			
Corporate tax	€M	-4.30	-4.34	-7.44
Equity associates	€M	-1.70	0.50	0.50
Minority interests	€M	0.70	0.00	0.00
Adjusted attributable net profit	€M	40.3	25.5	33.2
NOPAT	€M	54.0	34.1	42.1
Cashflow Statement				
EBITDA	€M	102	73.1	82.5
Change in WCR	€M	2.60	1.39	-0.11
Actual div. received from equity holdi	€M	0.00	0.00	0.00
Paid taxes	€M	-6.40	-4.34	-7.44
Exceptional items	€M			
Other operating cash flows	€M	-14.6	-8.00	-8.00
Total operating cash flows	€M	84.0	62.1	67.0
Capital expenditure	€M	-14.9	-16.5	-17.3
Total investment flows	€M	-76.9	-26.5	-27.3
Net interest expense	€M	-9.50	-10.5	-11.0
Dividends (parent company)	€M	-5.90	-18.8	-8.93
Dividends to minorities interests	€M	0.00	0.00	0.00
New shareholders' equity	€M	-0.10	0.00	0.00
Total financial flows	€M	111	-50.4	-48.9
Change in cash position	€M	115	-14.8	-9.25
Free cash flow (pre div.)	€M	59.6	35.1	38.7
Per Share Data				
No. of shares net of treas. stock (year	Mio	23.1	23.3	23.5
Number of diluted shares (average)	Mio	22.9	23.2	23.4
Benchmark EPS	€	1.76	1.10	1.42
Restated NAV per share	€			
Net dividend per share	€	1.32	0.60	0.65

© 2021, AlphaValue All rights reserved. Contract research, paid for by the above corporate entity. Equity research methods and procedures are as applied by AlphaValue. Target prices and opinions are thus exclusively determined by those methods and procedures. All opinions and estimates included herein represent the personal, technical judgment of the analyst as of the date of this report and are subject to change without prior notice. The information contained herein has been compiled from sources believed to be reliable, but while all reasonable care has been taken to ensure that the information contained herein is not untrue or misleading at the time of publication, we make no representation that it is accurate or complete and it should not be relied upon as such. AlphaValue does not accept any liability whatsoever for any direct or consequential loss arising from any use of this report or its contents, including the investment view held in this report.